Manufacturing is taking place in a well-equipped, up-to-date and efficient production facility comprising more than 8,000 m2 and including:
• cGMP-compliant documentation and equipment with capacity to manufacture batches ranging in size from a few kilos up to 700-800 kilos
• 30,000 liters reactor capacity increasing to 35.000 liters capacity with technologies to perform a wide variety of chemical reactions and final product handling
• Lean and experienced organization of 40 FTEs
COS has a documented capability to develop, register and market a broad range of synthetic active substances and holds certificates of suitability from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for several products. The facility has a history of developing more than 50 new APIs.
Today COS focuses on approximately 10 selected APIs and advanced intermediates. The main focus is on controlled substances comprising semi-synthetic opioids (morphine and thebaine based) and fully synthetic opioids (amphetamines). COS produces these substances using a variety of chemical synthetic methods in multi-step reactions and has the capability of producing batches ranging in size from a few kilos up to 700-800 kilos.
The selected product focus of COS is complementing its production setup, which is characterised by high flexibility and focus on small and medium-sized batches. In addition, COS is able to apply its in-house expertise to develop and optimise alternate synthetic routes and thereby optimising production efficiency.
We are also offering contract development and production services for new APIs and intermediates.